[go: up one dir, main page]

NO20033358L - Kombinasjoner av sterolabsorpsjonsinhibitor og kardiovaskul¶re midler for behandling av vaskul¶re lidelser - Google Patents

Kombinasjoner av sterolabsorpsjonsinhibitor og kardiovaskul¶re midler for behandling av vaskul¶re lidelser

Info

Publication number
NO20033358L
NO20033358L NO20033358A NO20033358A NO20033358L NO 20033358 L NO20033358 L NO 20033358L NO 20033358 A NO20033358 A NO 20033358A NO 20033358 A NO20033358 A NO 20033358A NO 20033358 L NO20033358 L NO 20033358L
Authority
NO
Norway
Prior art keywords
combinations
treatment
absorption inhibitor
vascular disorders
cardiovascular agents
Prior art date
Application number
NO20033358A
Other languages
English (en)
Other versions
NO20033358D0 (no
Inventor
Teddy Kosoglou
Rudyard Joseph Ress
John Strony
Enrico P Veltri
William Hauer
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27500817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20033358(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20033358D0 publication Critical patent/NO20033358D0/no
Publication of NO20033358L publication Critical patent/NO20033358L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20033358A 2001-01-26 2003-07-25 Kombinasjoner av sterolabsorpsjonsinhibitor og kardiovaskul¶re midler for behandling av vaskul¶re lidelser NO20033358L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26460001P 2001-01-26 2001-01-26
US26427501P 2001-01-26 2001-01-26
US26439601P 2001-01-26 2001-01-26
US32384201P 2001-09-21 2001-09-21
PCT/US2002/001196 WO2002058731A2 (en) 2001-01-26 2002-01-25 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions

Publications (2)

Publication Number Publication Date
NO20033358D0 NO20033358D0 (no) 2003-07-25
NO20033358L true NO20033358L (no) 2003-09-12

Family

ID=27500817

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033358A NO20033358L (no) 2001-01-26 2003-07-25 Kombinasjoner av sterolabsorpsjonsinhibitor og kardiovaskul¶re midler for behandling av vaskul¶re lidelser

Country Status (27)

Country Link
US (1) US20030069221A1 (no)
EP (3) EP2039357A2 (no)
JP (1) JP2004517919A (no)
KR (2) KR20080077033A (no)
CN (1) CN1582168A (no)
AR (2) AR032643A1 (no)
AT (1) ATE362757T1 (no)
AU (1) AU2002241903B2 (no)
BR (1) BR0206644A (no)
CA (1) CA2434436A1 (no)
CY (1) CY1106791T1 (no)
CZ (1) CZ20032031A3 (no)
DE (1) DE60220269T2 (no)
DK (1) DK1385548T3 (no)
EC (1) ECSP074704A (no)
ES (1) ES2286233T3 (no)
HU (1) HUP0303923A2 (no)
IL (2) IL156585A0 (no)
MX (1) MXPA03006724A (no)
NO (1) NO20033358L (no)
NZ (1) NZ545332A (no)
PL (1) PL369033A1 (no)
PT (1) PT1385548E (no)
RU (1) RU2003126186A (no)
SI (1) SI1385548T1 (no)
SK (1) SK9492003A3 (no)
WO (1) WO2002058731A2 (no)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
SK288217B6 (sk) 2001-01-26 2014-08-05 Merck Sharp & Dohme Corp. Zmes, terapeutická kombinácia, farmaceutický prostriedok a ich použitie
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
BRPI0206641B8 (pt) 2001-01-26 2021-05-25 Merck Sharp & Dohme uso de um inibidor da absorção de esteróis
AR035739A1 (es) * 2001-01-26 2004-07-07 Schering Corp Composiciones farmaceuticas y combinaciones terapeuticas que comprenden secuestrante (s) de los acidos biliares y de inhibidor (es) de la absorcion de los esteroles y el uso de dichas composiciones para la manufactura de un medicamento para el tratamiento de indicaciones vasculares
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
SI1427409T1 (sl) * 2001-09-21 2009-02-28 Schering Corp Postopki za zdravljenje ali preprečevanje vaskularnega vnetja z uporabo zaviralca(-ev) absorpcije sterola
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
DE60216300T2 (de) 2001-09-21 2007-06-28 Schering Corp. Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
US20040063717A1 (en) * 2002-05-21 2004-04-01 Andrew Wolff Method of treating diabetes
US6861553B2 (en) 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7534913B2 (en) * 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US7420084B2 (en) * 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US20050075400A1 (en) * 2002-07-18 2005-04-07 Ronit Yahalomi Polymorphic forms of nateglinide
US7148376B2 (en) * 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7358390B2 (en) * 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
AU2003270909A1 (en) * 2002-09-27 2004-04-19 Martek Biosciences Corporation Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
AU2003291719A1 (en) * 2002-11-06 2004-06-03 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
CA2517573C (en) 2003-03-07 2011-12-06 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
ES2311806T3 (es) * 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
US20060217421A1 (en) * 2003-05-09 2006-09-28 Hajimu Kurumatani Fortifier
JP2005015434A (ja) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
WO2005018561A2 (en) * 2003-08-20 2005-03-03 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
AU2008201290B2 (en) * 2003-09-26 2010-12-09 Astrazeneca Uk Limited Therapeutic treatment
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
ATE485267T1 (de) 2003-12-23 2010-11-15 Astrazeneca Ab Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung
JP5697296B2 (ja) 2004-03-05 2015-04-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 高脂血症および高コレステロール血症に関連する障害または疾患を、副作用を最小限にしつつ処置するための方法
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
EP1750862B1 (en) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
AP2764A (en) * 2005-01-31 2013-09-30 Mylan Lab Inc Hydroxylated nebivolol metabolites
RU2441653C2 (ru) * 2005-05-31 2012-02-10 Милан Лэборетериз, Инк. Композиции, содержащие небиволол
CA2610694A1 (en) * 2005-05-31 2006-12-07 Mylan Laboratories, Inc. Compositions comrising nebivolol
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
CA2616806A1 (en) * 2005-07-28 2007-02-08 Reliant Pharmaceuticals, Inc. Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof
JP2009503075A (ja) * 2005-08-01 2009-01-29 シヴィダ・インコーポレイテッド ＨＭＧＣｏＡ還元酵素インヒビターコドラッグ及びその使用
DK1942895T3 (da) * 2005-09-15 2012-03-05 Otsuka Pharma Co Ltd Kombinationslægemiddel indeholdende probucol og et tetrazolylalkoxy-dihydrocarbostyrilderivat med superoxidhæmmende virkninger
US20080253985A1 (en) * 2005-10-18 2008-10-16 Wisler Gerald L Compositions for Lowering Serum Cholesterol and/or Triglycerides
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
US20080139527A1 (en) * 2006-12-08 2008-06-12 Reddy Kota J Methods for treatment of heart disease
WO2008076841A1 (en) * 2006-12-14 2008-06-26 Biokey, Inc. Pharmaceutical composition for reducing the risks associated with cardiovascular and cerebrovascular diseases
AU2007338625A1 (en) * 2006-12-21 2008-07-03 Aegerion Pharmaceuticals, Inc. Methods for treating obesity with a combination comprising a MTP inhibitor and a cholesterol absorption inhibitor
CA2678325A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
CA2677931A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
JP2010518170A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 冠微小血管疾患の処置のためのラノラジンの使用
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
EA200971073A1 (ru) * 2007-05-31 2010-08-30 Джилид Пало Альто, Инк. Применение ранолазина при повышенном уровне натрийуретического пептида мозгового типа
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JP5546451B2 (ja) 2007-06-04 2014-07-09 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
EP2042179A1 (en) * 2007-09-26 2009-04-01 sanofi-aventis Novel therapeutic uses of adrenergic alpha-1 receptor antagonists
KR20090091083A (ko) * 2008-02-22 2009-08-26 한올제약주식회사 방출성이 제어된 심혈관계질환 치료용 약제학적 제제
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9388440B2 (en) 2009-04-01 2016-07-12 Mylan Laboratories Limited Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of Ezetimibe and further conversion to Ezetimibe
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
KR101708538B1 (ko) * 2011-08-26 2017-02-20 욱크하르트 리미티드 심혈관 질환의 치료 방법
EP2727587A1 (en) * 2012-10-30 2014-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
HK1220696A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 鸟苷酸环化酶激动剂及其用途
EP4424697A3 (en) 2013-06-05 2024-12-25 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
KR20150120008A (ko) * 2014-04-16 2015-10-27 씨제이헬스케어 주식회사 비소프롤롤 및 로수바스타틴을 포함하는 경구용 약제학적 복합제제
WO2016155815A1 (en) * 2015-04-01 2016-10-06 Ceva Sante Animale Oral solid dosage form of amlodipine and veterinary uses thereof
AU2021316011A1 (en) 2020-07-29 2023-02-09 Amryt Pharmaceuticals Inc. Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients
KR102816341B1 (ko) * 2022-01-24 2025-06-05 연세대학교 산학협력단 심혈관계 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3108097A (en) * 1963-10-22 Ehnojs
US1286A (en) * 1839-08-13 Richard else
US2809194A (en) * 1957-10-08 Thiadiazine type natriuretic agents
BE578515A (no) * 1958-05-07
NL127065C (no) * 1964-04-22
NL137318C (no) * 1964-06-09
FI52570C (fi) * 1969-04-16 1977-10-10 Sumitomo Chemical Co Menetelmä veren kolesteroli- tai lipoidipitoisuutta alentavien fenoxia lifaattisten karboksyylihappoyhdisteiden ja -esteriyhdisteiden valmist amiseksi.
US3692895A (en) * 1970-09-08 1972-09-19 Norman A Nelson Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
DE2230383C3 (de) * 1971-10-01 1981-12-03 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben
US4148923A (en) * 1972-05-31 1979-04-10 Synthelabo 1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity
US3948973A (en) * 1972-08-29 1976-04-06 Sterling Drug Inc. Halocyclopropyl substituted phenoxyalkanoic acids
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
US4179515A (en) * 1975-02-12 1979-12-18 Orchimed S. A. Benzoylphenoxy propionic acid, esters thereof and pharmaceutical composition
JPS5195049A (en) * 1975-02-12 1976-08-20 * **********so*****no***tsu*****************************************ni*no
US4235896A (en) * 1975-02-12 1980-11-25 Orchimed S.A. Benzyl-phenoxy acid esters and hyperlipaemia compositions containing the same
US4075000A (en) * 1975-05-27 1978-02-21 Eli Lilly And Company Herbicidal use of 4-amino-3,3-dimethyl-1-phenyl-2-azetidinones
US4576753A (en) * 1975-10-06 1986-03-18 Fujisawa Pharmaceutical Co., Ltd. Azetidinone compounds and processes for preparation thereof
US4304718A (en) * 1975-10-06 1981-12-08 Fujisawa Pharmaceutical Co., Ltd. 2-Azetidinone compounds and processes for preparation thereof
US4472309A (en) * 1975-10-06 1984-09-18 Fujisawa Pharmaceutical Co., Ltd. 2-Azetidinone compounds and processes for preparation thereof
US4166907A (en) * 1976-11-01 1979-09-04 E. R. Squibb & Sons, Inc. 3,3-Dichloro-2-azetidinone derivatives having antiinflammatory activity
US4144232A (en) * 1976-12-23 1979-03-13 Eli Lilly And Company Substituted azetidin-2-one antibiotics
FR2403078A1 (fr) * 1977-09-19 1979-04-13 Lafon Labor Nouveau procede de preparation de formes pharmaceutiques, cosmetiques ou de diagnostic
IT1157365B (it) * 1977-10-24 1987-02-11 Sandoz Ag Medicamenti per trattare l'obesita' o ridurre il peso del corpo
US4250191A (en) * 1978-11-30 1981-02-10 Edwards K David Preventing renal failure
US4375475A (en) * 1979-08-17 1983-03-01 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis
US4260743A (en) * 1979-12-31 1981-04-07 Gist-Brocades N.V. Preparation of β-lactams and intermediates therefor
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DE3107100A1 (de) * 1981-02-20 1982-09-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Azaprostacycline, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
US4500456A (en) * 1981-03-09 1985-02-19 Eli Lilly And Company Preparation of 4-fluoroazetidinones using FClO3
US4784734A (en) * 1981-04-10 1988-11-15 Otsuka Kagaku Yakuhin Kabushiki Kaisha Azetidinone derivatives and process for the preparation of the same
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4443372A (en) * 1982-06-23 1984-04-17 Chevron Research Company 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
US4534786A (en) * 1982-06-23 1985-08-13 Chevron Research Company 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
US4595532A (en) * 1983-02-02 1986-06-17 University Of Notre Dame Du Lac N-(substituted-methyl)-azetidin-2-ones
CA1256650A (en) * 1983-03-25 1989-06-27 Toshinari Tamura Process of producing 2-azetidinone-4-substituted compounds, and medicaments containing the compounds
EP0126709B1 (de) * 1983-03-28 1991-04-03 Ciba-Geigy Ag Verfahren zur Herstellung von optisch aktiven Azetidinonen
US4675399A (en) * 1983-03-28 1987-06-23 Notre Dame University Cyclization process for β-lactams
WO1985004876A1 (fr) * 1984-04-24 1985-11-07 Takeda Chemical Industries, Ltd. Derives de 2-azetidinone et leur procede de preparation
US4576749A (en) * 1983-10-03 1986-03-18 E. R. Squibb & Sons, Inc. 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5229510A (en) * 1983-12-01 1993-07-20 Merck & Co., Inc. β-lactams useful in determining the amount of elastase in a clinical sample
US5229381A (en) * 1983-12-01 1993-07-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US4654362A (en) * 1983-12-05 1987-03-31 Janssen Pharmaceutica, N.V. Derivatives of 2,2'-iminobisethanol
FR2561916B1 (fr) * 1984-03-30 1987-12-11 Lafon Labor Forme galenique pour administration orale et son procede de preparation par lyophilisation d'une emission huile dans eau
US4633017A (en) * 1984-08-03 1986-12-30 E. R. Squibb & Sons, Inc. N-hydroxy protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4581170A (en) * 1984-08-03 1986-04-08 E. R. Squibb & Sons, Inc. N-hydroxyl protecting groups and process and intermediates for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4576748A (en) * 1984-09-17 1986-03-18 Merck & Co., Inc. 3-Hydroxy-3-aminoethyl β-lactams
US4620867A (en) * 1984-09-28 1986-11-04 Chevron Research Company 1-carbalkoxyalkyl-3-aryloxy-4-(substituted-2'-carboxyphenyl)-azet-2-ones as plant growth regulators and herbicides
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US4642903A (en) * 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US4680289A (en) * 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
DE3787815T2 (de) * 1986-02-19 1994-03-24 Sanraku Inc Azetidinonderivate.
GB8607312D0 (en) * 1986-03-25 1986-04-30 Ici Plc Therapeutic agents
FR2598146B1 (fr) * 1986-04-30 1989-01-20 Rech Ind Nouveau procede de preparation de fibrates.
DE3621861A1 (de) * 1986-06-30 1988-01-14 Laszlo Dr Med Ilg Verwendung von aryloxycarbonsaeure-derivaten gegen dermatologische erkrankungen
FR2602423B1 (fr) * 1986-08-08 1989-05-05 Ethypharm Sa Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
US4814354A (en) * 1986-09-26 1989-03-21 Warner-Lambert Company Lipid regulating agents
US4803266A (en) * 1986-10-17 1989-02-07 Taisho Pharmaceutical Co., Ltd. 3-Oxoalkylidene-2-azetidinone derivatives
US5229362A (en) * 1986-12-15 1993-07-20 Eli Lilly And Company Antibiotic A10255 complex and factors, and process and production therefor
JPS63156788A (ja) * 1986-12-22 1988-06-29 Sanraku Inc 光学活性アゼチジノン類
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US4879301A (en) * 1987-04-28 1989-11-07 Hoei Pharmaceutical Co., Ltd. Antiallergic and antiinflammatory benzothiazolinone derivatives
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US5091525A (en) * 1987-10-07 1992-02-25 Eli Lilly And Company Monohydrate and DMF solvates of a new carbacephem antibiotic
US4834846A (en) * 1987-12-07 1989-05-30 Merck & Co., Inc. Process for deblocking N-substituted β-lactams
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
DE3807895A1 (de) * 1988-03-10 1989-09-21 Knoll Ag Erzeugnisse, enthaltend einen calciumantagonisten und einen lipidsenker
GB8813012D0 (en) * 1988-06-02 1988-07-06 Norsk Hydro As Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals
US4952689A (en) * 1988-10-20 1990-08-28 Taisho Pharmaceutical Co., Ltd. 3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
US4876365A (en) * 1988-12-05 1989-10-24 Schering Corporation Intermediate compounds for preparing penems and carbapenems
US5260305A (en) * 1988-12-12 1993-11-09 E. R. Squibb & Sons, Inc. Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
FR2640621B1 (fr) * 1988-12-19 1992-10-30 Centre Nat Rech Scient N-aryl-azetidinones, leur procede de preparation et leur utilisation comme inhibiteurs des elastases
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
JPH03108490A (ja) * 1989-06-30 1991-05-08 Shionogi & Co Ltd フォスフォリパーゼａ↓２阻害物質
US5021461A (en) * 1989-07-26 1991-06-04 Merrell Dow Pharmaceuticals Inc. Method of treating diabetes mellitus with bisphenol derivatives
US4983597A (en) * 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5219574A (en) * 1989-09-15 1993-06-15 Cima Labs. Inc. Magnesium carbonate and oil tableting aid and flavoring additive
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5223264A (en) * 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
US5120729A (en) * 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
US5120713A (en) * 1990-09-10 1992-06-09 Applied Research Systems Ars Holding N.V. Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
JP2640986B2 (ja) * 1990-11-08 1997-08-13 高砂香料工業株式会社 （１′ｒ，３ｓ）―３―（１′―ヒドロキシエチル）―アゼチジン―２―オン又はその誘導体の製造法
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
US5278176A (en) * 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
AU2943095A (en) * 1994-06-20 1996-01-15 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
JP3144624B2 (ja) * 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
GB9600464D0 (en) * 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
DE69911058T2 (de) * 1998-12-23 2004-06-03 G.D. Searle Llc, Chicago Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen
US20020013334A1 (en) * 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
PE20020453A1 (es) * 2000-09-27 2002-06-06 Merck & Co Inc Derivados del acido benzopirancarboxilico para el tratamiento de la diabetes y los trastornos de lipidos
HUP0401073A2 (hu) * 2000-12-21 2004-09-28 Aventis Pharma Deutschland Gmbh. Difenilazetidinon-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ES2277890T3 (es) * 2000-12-21 2007-08-01 Sanofi-Aventis Deutschland Gmbh Nuevas difenilazetidinonas, procedimiento para su preparacion, medicamentos que contienen estos compuestos y su uso para el tratamiento de trastornos del metabolismo de lipidos.
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
US7091230B2 (en) * 2001-02-09 2006-08-15 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
CA2439920A1 (en) * 2001-03-08 2002-09-19 Merck & Co., Inc. Antihypertensive agent and cholesterol absorption inhibitor combination therapy
WO2002081454A1 (en) * 2001-04-09 2002-10-17 Dr. Reddy's Laboratories Ltd. Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
IL190173A0 (en) 2008-08-07
CA2434436A1 (en) 2002-08-01
ES2286233T3 (es) 2007-12-01
ATE362757T1 (de) 2007-06-15
EP2039357A2 (en) 2009-03-25
RU2003126186A (ru) 2005-03-10
HK1060854A1 (en) 2004-08-27
IL156585A0 (en) 2004-01-04
EP1541175A3 (en) 2006-04-12
DE60220269D1 (de) 2007-07-05
US20030069221A1 (en) 2003-04-10
AU2002241903B2 (en) 2005-11-24
CY1106791T1 (el) 2012-05-23
PT1385548E (pt) 2007-08-24
AR066143A2 (es) 2009-07-29
KR20040025889A (ko) 2004-03-26
MXPA03006724A (es) 2003-10-24
ECSP074704A (es) 2008-01-23
DK1385548T3 (da) 2007-09-10
KR20080077033A (ko) 2008-08-20
NZ545332A (en) 2007-09-28
EP1385548A2 (en) 2004-02-04
BR0206644A (pt) 2004-02-25
CN1582168A (zh) 2005-02-16
NO20033358D0 (no) 2003-07-25
EP1541175A2 (en) 2005-06-15
HUP0303923A2 (hu) 2004-03-01
WO2002058731A2 (en) 2002-08-01
PL369033A1 (en) 2005-04-18
EP1385548B1 (en) 2007-05-23
CZ20032031A3 (cs) 2003-12-17
WO2002058731A3 (en) 2003-11-20
AR032643A1 (es) 2003-11-19
JP2004517919A (ja) 2004-06-17
DE60220269T2 (de) 2008-01-17
SK9492003A3 (en) 2003-12-02
SI1385548T1 (sl) 2007-10-31

Similar Documents

Publication Publication Date Title
NO20033358L (no) Kombinasjoner av sterolabsorpsjonsinhibitor og kardiovaskul¶re midler for behandling av vaskul¶re lidelser
NO20033357D0 (no) Kombinasjoner av sterolabsorpsjonsinhibitor og blodmodifiserende middel forbehandling av vaskul¶re lidelser
ATE348649T1 (de) Kombinationen von einem hemmer der sterol- absorption und einem ppar-aktivator zur behandlung von kardiovaskulären indikationen
NO20026008D0 (no) Fremgangsmåte for behandling av cardiovaskul¶re sykdommer
ATE369851T1 (de) Kombinationen von gallensäuresequestriermitteln und hemmern der sterolabsorption zur behandlung von kardiovaskulären indikationen
DK1487541T3 (da) Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelse af perifere vaskulære sygdomme
DE60032823D1 (de) Adamantanderivate zur Behandlung von entzündlichen, immunologischen und kardiovaskulären Erkrankungen
NO20044195L (no) Biofosfoninsyrer for behandling og prevensjon av osteoprose
MXPA03006727A (es) Combinaciones de acido nicotinico y derivados del mismo con inhibidor(es) de la absorcion de los esteroles, y tratamiento para indicaciones vasculares.
NO20043984L (no) Ko-terapi for behandling av migrene omfattende antikonvulsantderivater og anti-migrenemidler
EP1335736A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF HEART CIRCULAR DISEASES
NO20015772L (no) Forbindelser og fremgangsmåter for behandling av post- traumatisk stress-syndrom
DK1355668T3 (da) Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom
NO20033117L (no) Farmasöytiske blandinger som inhiberer vaskul¶r proliferasjon og metoder for anvendelse derav
NO20043029L (no) Karboksamidinderivater og deres anvendelse ved behandling av vaskulaere sykdommer
NO20035299D0 (no) Preparater og syklooksygenase-2-selektive inhibitorer og bestråling for inhibering eller forhindring av kardiovaskul¶re sykdommer
PL371436A1 (en) Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders
NO20014976L (no) Dibenzoazulenderivater for behandling av trombose, osteoporose og arteriosklerose
DE50301547D1 (de) Chinoxalinone und ihre verwendung insbesondere in der behandlung von cardiovaskularen erkraunkungen
NO20054020D0 (no) Medisin for forhindring og behandling av arterosklerose og hypertensjon
IL151658A0 (en) Methods and compositions for the treatment or prevention of cardiovascular diseases

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application